These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 26800210)

  • 1. Cotton Wool Spots after Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Associated with Central Retinal Vein Occlusion.
    Kida T; Tsujikawa A; Muraoka Y; Harino S; Osaka R; Murakami T; Ooto S; Suzuma K; Morishita S; Fukumoto M; Suzuki H; Ikeda T
    Ophthalmologica; 2016; 235(2):106-13. PubMed ID: 26800210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
    Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
    Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
    Eadie JA; Ip MS; Kulkarni AD
    Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
    Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.
    Lehmann-Clarke L; Dirani A; Mantel I; Ambresin A
    Klin Monbl Augenheilkd; 2015 Apr; 232(4):552-5. PubMed ID: 25902119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion.
    Kaya F; Kocak I; Aydin A; Baybora H; Koc H; Karabela Y
    J Fr Ophtalmol; 2018 Nov; 41(9):809-813. PubMed ID: 30361176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab.
    Papakostas TD; Lim L; van Zyl T; Miller JB; Modjtahedi BS; Andreoli CM; Wu D; Young LH; Kim IK; Vavvas DG; Esmaili DD; Husain D; Eliott D; Kim LA
    Eye (Lond); 2016 Jan; 30(1):79-84. PubMed ID: 26449196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
    Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA
    Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.
    Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T
    Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.
    Chatziralli I; Theodossiadis G; Moschos MM; Mitropoulos P; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1093-1100. PubMed ID: 28214955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion.
    Yucel OE; Birinci H; Sullu Y
    Int Ophthalmol; 2019 Apr; 39(4):891-901. PubMed ID: 29550932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.
    Cohen MN; Houston SK; Juhn A; Ho AC; Regillo CD; Vander J; Chiang A
    Can J Ophthalmol; 2016 Oct; 51(5):342-347. PubMed ID: 27769324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SCORE2 Report 2: Study Design and Baseline Characteristics.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Figueroa M; Dugel PU;
    Ophthalmology; 2017 Feb; 124(2):245-256. PubMed ID: 27863843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Intravitreal Ranibizumab, Aflibercept, and Dexamethasone Implant after Bevacizumab Failure in Macular Edema Secondary to Retinal Vascular Occlusions.
    Hanhart J; Rozenman Y
    Ophthalmologica; 2017; 238(1-2):110-118. PubMed ID: 28535531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion.
    Hogg HJ; Di Simplicio S; Pearce MS
    Eur J Ophthalmol; 2021 Mar; 31(2):548-555. PubMed ID: 32009462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.
    Kaldırım HE; Yazgan S
    Int Ophthalmol; 2018 Aug; 38(4):1549-1558. PubMed ID: 28646440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
    Zhou S; Gao J; Xu X
    Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Retinal Microvasculature and Visual Acuity After Antivascular Endothelial Growth Factor Therapy in Retinal Vein Occlusion.
    Winegarner A; Wakabayashi T; Fukushima Y; Sato T; Hara-Ueno C; Busch C; Nishiyama I; Shiraki N; Sayanagi K; Nishida K; Sakaguchi H; Nishida K
    Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):2708-2716. PubMed ID: 29860457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arm-to-retina time predicts visual outcome of anti-vascular endothelial growth factor treatment for macular edema due to central retinal vein occlusion.
    Takei T; Nagai N; Ohkoshi K; Ozawa Y
    Sci Rep; 2022 Feb; 12(1):2194. PubMed ID: 35140311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.
    Boyer D; Heier J; Brown DM; Clark WL; Vitti R; Berliner AJ; Groetzbach G; Zeitz O; Sandbrink R; Zhu X; Beckmann K; Haller JA
    Ophthalmology; 2012 May; 119(5):1024-32. PubMed ID: 22440275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.